ERNA · Categories · Form 4

ERNA - SEC Form 4 insider transactions

Ernexa Therapeutics Inc. (ERNA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ERNA

• 293d
  Sr. VP of Finance Gurrola Sandra M converted options into 30 shares, increasing direct ownership by 38% to 110 units (SEC Form 4)

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 440d
  SEC Form 4 filed by Director Wexler William A.

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 440d
  SEC Form 4 filed by Sr. VP of Finance Gurrola Sandra M

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 440d
  SEC Form 4 filed by Director Bristol James Arthur

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 440d
  SEC Form 4 filed by Director Cicala Peter

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 440d
  SEC Form 4 filed by President & CEO Luther Sanjeev

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 467d
  SEC Form 4 filed by Director Ratner Elena

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 670d
  Sr. VP of Finance Gurrola Sandra M converted options into 437 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 28% to 1,185 units (SEC Form 4)

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 727d
  SEC Form 4 filed by Cicala Peter

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 727d
  SEC Form 4 filed by Bristol James Arthur

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 727d
  SEC Form 4 filed by Gurrola Sandra M

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

Other ERNA categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends